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Aims. Fibrin formation and histidine-rich glycoprotein (HRG) are involved in primary hemostasis and wound healing. Little is
known regarding the relationship of clot characteristics, bleeding time, and wound healing. Methods and Results. We studied
154 patients with coronary artery disease (CAD) and 154 subjects free of CAD matched for age, obesity, and current smoking.
We evaluated bleeding time (BT) using standardized skin incisions on a forearm, along with plasma clot permeability (Ks), clot
lysis time (CLT), and histidine-rich glycoprotein (HRG). Compared with controls, BT was 45% shorter in CAD cases. CAD
patients had 32% lower Ks and 17% longer CLT as well as 50% lower HRG compared with controls (all p < 0:001). After
adjusting for potential confounders, Ks and HRG levels were independent predictors of prolonged BT in CAD patients (OR
23.70, 95% CI 4.65-120.8 and OR 10.27, 95% CI 2.05-51.31, respectively) and controls (OR 10.89, 95% CI 2.31-51.11 and OR
4.54, 95% CI 1.07-19.27, respectively). Scar formation (n = 79, 25.6%) was independently predicted by both short and prolonged
BT in CAD cases (OR 21.87, 95% CI 7.41-64.55 and OR 10.17, 95% CI 2.88-35.97) and controls (OR 5.94, 95% CI 2.29-15.41
and OR 14.76, 95% CI 4.29-50.77, respectively). Conclusions. The study shows that plasma fibrin clot density and HRG may
influence BT and that appropriate skin wound healing is associated with medium BT. Translational Perspective. Elucidation of
the complex relationships between plasma fibrin clot phenotype and wound healing might have important practical implications.
1. Introduction
Fibrin formation is the final step of blood coagulation
involved in hemostasis following vascular injury and the
maintenance of vessel patency under pathological conditions.
There is evidence that plasma fibrin clots composed of com-
pact networks that are less susceptible to lysis, the so-called
“prothrombotic clot phenotype,” can be observed in patients
with myocardial infarction (MI), ischemic stroke, and
peripheral artery disease [1, 2]. Unfavourable fibrin clot char-
acteristics were also found in patients with cardiovascular
risk factors, including cigarette smoking [3], diabetes mellitus
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[4], and arterial hypertension [5]. The impact of environ-
mental factors is considered prevalent in the prothrombotic
plasma clot phenotype [6, 7]. Some medications, in particular
aspirin and statins, have been reported to increase clot per-
meability and susceptibility to lysis [8, 9]. Of importance,
recent studies have suggested that clot properties may predict
recurrent thrombosis [10].
Fibrin is essential for wound healing as it provides a scaf-
fold for macrophages and fibroblasts migrating into the
wound [11]. Fibrin acts together with platelets producing
growth factors necessary for recruitment and activation of
fibroblasts [12]. Fibrin forms a network stabilizing aggre-
gated platelets. Endothelial cells (ECs) invade the wound
soon after leukocytes and monocytes and bind to fibrin with
integrins [12]. ECs are activated by vascular endothelial
growth factor (VEGF), fibroblast growth factor-2 (FGF-2),
fibronectin, and also fibrin while platelet factor-4 (PF4) is
one of the most important inhibitors of angiogenesis. Fibrin-
ogen bound to the integrins exposed on the surface of the
nucleated cells is necessary to trigger change of cell shape
and proper contraction of the wound [12]. The role of abnor-
mal fibrin clot features in defective wound healing has been
suggested by clinical phenotypes of some dysfibrinogenae-
mias [13–15]. Application of a fibrin sealant to the wound
accelerates its healing, probably due to improved prolifera-
tion and migration of fibroblasts [12]. However, exact rela-
tionships between fibrin clot properties assessed in plasma,
bleeding time (BT), and the wound healing in human sub-
jects remain unclear. Furthermore, we hypothesized that
histidine-rich glycoprotein (HRG) may play role in these
relationships. HRG is a liver-produced ~75 kDa single poly-
peptide chain protein [16] present at ~1.5μM concentration
in human plasma [17]. HRG binds to a diverse range of
ligands (fibrin, fibrinogen, plasminogen, heparin, heparan
sulfate, thrombospondin, complement C1q, immunoglobu-
lin G, heme, zinc ions, phospholipids, etc.). This may imply
its regulatory role for immune, vascular, and coagulation sys-
tems [17–19].
Standardized skin incisions performed with a single-use
device (e.g., SimPlate or Surgicutt) have been long employed
to measure BT in patients suspected of bleeding disorders
[20, 21]. Blood coagulation initiated by skin incisions
depends on the tissue factor- (TF-) mediated extrinsic path-
way with massive thrombin generation in blood collected at
the site of injury [22]. Prolonged BT has been shown in, i.e.,
hemophilia or afibrinogenemia [23, 24]. Interestingly, it has
been shown that fibrin formation occurs as early as 30-60
seconds after the skin incision in healthy humans [25]. It is
however unclear whether fibrin clot characteristics affect
BT in subjects free of bleeding tendency.
To our knowledge, there have been no studies explor-
ing plasma clot features in relation to BT and skin wound
healing in healthy subjects and patients with coronary
artery disease (CAD) known to form denser fibrin clot
structures [6, 7, 9]. We hypothesized that looser fibrin fibre
networks prolong BT and impair skin wound healing. We
sought to investigate whether plasma clot properties affect
BT and scar formation at the site of standardized skin
incisions in humans.
2. Materials and Methods
2.1. Patients. We assessed 154 consecutive patients (cases)
with stable CAD (Canadian Cardiovascular Society classes
II or III) and, as controls, 154 unrelated subjects free of CAD,
who were recruited from the hospital personnel or family mem-
bers. All study participants were enrolled between 1999 and
2007 and were partly described previously [9, 22]. Patients were
excluded if they had any acute illness, known cancer, chronic
inflammatory disease (C − reactive protein ½CRP > 10mg/L),
liver injury (alanine transaminase > 1:5 times above the
upper limit of the reference range), glomerular filtration
rate ðGFRÞ < 30mL/min, prior venous thromboembolism
or stroke, any acute coronary syndrome (ACS) within the
6 preceding months, and current antithrombotic treatment
other than acetylsalicylic acid (ASA). The subjects with poor
skin condition including scars, edema, atrophy (also all
treated with corticosteroids) were ineligible.
Obesity was defined as bodymass index ðBMIÞ ≥ 30 kg/
m2. Diabetes was defined as a history of diabetes, the use of
hypoglycemic agents, or fasting plasma glucose ≥126mg/dL
(7mM) on two separate occasions. Arterial hypertension
was defined as a systolic and/or a diastolic blood pressure ≥
140mmHg or ≥90mmHg, respectively, or antihypertensive
therapy. Heart failure was defined according to the Euro-
pean guidelines [26]. Anemia was defined as hemoglobin
levels < 120 g/L.
The study was performed in accordance with the Decla-
ration of Helsinki and its protocol was approved by the Bio-
ethical Committee of the Jagiellonian University. All subjects
enrolled provided written informed consent.
2.2. Laboratory Investigations. Fasting blood was drawn from
an antecubital vein with minimal stasis between 8 and11 AM.
Lipid profiles, blood cell counts, glucose, creatinine, D-dimer,
international normalized ratio (INR), and activated partial
thromboplastin time (APTT) were assayed by routine labora-
tory techniques. Factor VIII activity (FVIII) was measured by
one-stage clotting assay using factor-deficient plasma (Siemens,
Marburg, Germany). Fibrinogen was determined using the von
Clauss method. High-sensitivity CRP was measured by nephe-
lometry (Siemens, Marburg, Germany). Fasting plasma tHcy
levels were measured using HPLC. Histidine-rich glycoprotein
(HRG) and VEGF levels were measured using ELISAs (R&D
Systems Inc., Abington, UK). The two parameters were
assessed in once thawed samples frozen at -80 degrees Celsius.
The interassay and intra-assay coefficients of variation for the
ELISAs were <8%.
2.3. Bleeding Time. BT assessment was performed by 2
experienced investigators as described previously [27]. In
brief, after compressing the upper arm with a sphygmo-
manometer cuff to 40mm Hg, two incisions were made
on the apparently healthy skin of the lateral aspect of a
forearm parallel to the antecubital crease using a Simplate
II device (Organon Teknika, Durham, NC, USA). The
blood shed from incisions was collected at 30-second
intervals and BT was recorded when blood flow ceased
in two wounds.
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2.4. Fibrin Clot Properties. Plasma samples (9 : 1 of 3.2% triso-
dium citrate) for fibrin assays were centrifuged (20min,
2500 g) within 30 minutes of collection to obtain platelet-
poor plasma, immediately frozen, and stored in aliquots at
-80°C. All measurements were performed by technicians
blinded to the sample status in the material stored at -80
degrees Celsius and thawed prior to analysis.
2.4.1. Clot Permeability. Permeation of plasma fibrin clots
was determined as described [9]. Briefly, 20mM calcium
chloride and 1U/mL human thrombin (Sigma-Aldrich/-
Merck, Darmstadt, Germany) were added to citrated plasma.
Tubes containing the clots were connected to a reservoir of a
Tris-buffered saline (TBS) buffer (0.01M Tris, 0.1M NaCl,
pH 7.5), and its volume flowing through the gels was mea-
sured within 60 minutes. A permeation coefficient (Ks), indi-
cating the pore size, was calculated from the equation:
Ks =Q × L × η/t × A × Δp, where Qis the flow rate in time t,
L is the length of a fibrin gel, η is the viscosity of liquid
(in poise), t is percolating time, A is the cross-sectional area
(in cm2), and Δp is a differential pressure (in dyne/cm2).
The intraindividual variability of results was 8%.
2.4.2. Clot Lysis Time. CLT was measured as described [28,
29]. Briefly, citrated plasma was mixed with 15mM calcium
chloride, 10,000-diluted human TF (Innovin, Siemens, Mar-
burg, Germany), 12μM phospholipid vesicles (highly purified
phosphatidylcholine, phosphatidylserine, and sphingomyelin
from Rossix, Molndal, Sweden), and 60ng/ml recombinant
t-PA (Boehringer Ingelheim, Ingelheim, Germany). The mix-
ture was transferred to a microtiter plate and its turbidity
was measured at 405nm at 37°C. Clot lysis time was
defined as the time from the midpoint of the clear-to-max-
imum-turbid transition, which represents clot formation, to
the midpoint of the maximum-turbid-to-clear transition.
The coefficients of intra- and interassay variations were 6%.
2.5. Scar Formation. Formation of the scar at the site of prior
BT test was assessed macroscopically by the independent
investigators two weeks after BT measurement. The scar
was defined as a linear mark at the site of skin incision differ-
ent in colour from the surrounding skin and >1mm wide.
The interobserver variability was estimated at 10%, based
on evaluation of 50 randomly selected patients performed
independently by 2 investigators.
All methods were performed in accordance with the rel-
evant guidelines and regulations.
2.6. Statistical Analysis. The study was powered to have a 90%
chance of detecting a 10% difference in Ks using a p value of
0.05. To demonstrate such a difference or greater in Ks, at
least 31 patients were required in each group [9].
Categorical variables were compared using χ2 exact test.
Continuous variables were tested for the normality of the dis-
tribution by the Shapiro-WilkW test. Those normally distrib-
uted are given as themean ± standard deviation and otherwise
as median (interquartile range). Comparisons were performed
using unpaired (Student’s) t-test or Mann–Whitney U test,
respectively. Associations between continuous variables were
calculated using Spearman’s rank correlation coefficient.
Uni- and multivariate logistic regression models were used
to determine predictors of scar formation. We determined
predictors of long and short BT, defined as the upper and
the lower BT quartile, respectively, along with predictors of a
very long BT with its 90th percentile as a cutoff value. Multi-
variate analyses adjusted for age, diabetes, ASA use, and statin
treatment. Models for BT prediction involved also current
smoking, platelet count, FVIII, CLT, Ks, and HRG. A p value
of less than 0.05 was considered significant. Statistical analyses
were conducted using the Statistica 64 v.13 (StatSoft/Dell,
Tulsa, OK, USA) or MedCalc 64-bit v.13.1.2.0 (MedCalc
Software, Ostend, Belgium) program.
3. Results
3.1. Characteristics of the Studied Groups. The CAD group
had a lower proportion of females and a higher prevalence
of hypertension, diabetes, higher BMI, total cholesterol, and
LDL cholesterol as well as a more frequent statin use, com-
pared with controls (Table 1). Fibrinogen and FVIII levels
were higher in CAD patients than controls (Table 1).
3.2. Bleeding Time. BT was 45% shorter in CAD patients than
controls (Table 1). An inverse correlation between BT and
age was observed only in controls (R = −0:54, p < 0:001). As
expected, BT was longer in CAD patients treated by ASA
(250 [211-309] vs. 229 [199-275] sec, respectively, p = 0:03),
while those on statins had shorter BT (210 [195-250] vs.
240 [207-296] sec, respectively, p = 0:01).
In the CAD and control groups, there were inverse corre-
lations between BT and fibrinogen (R = −0:30, p < 0:001 and
R = −0:52, p < 0:001, respectively) and platelet count
(R = −0:51, p < 0:001 and R = −0:45, p < 0:001, respectively).
There was an inverse weak correlation between BT and FVIII
(R = −0:21, p = 0:01) in controls who all had FVIII above 80%.
3.3. HRG and VEGF. Plasma HRG levels were 50% lower in
CAD patients than in controls (Table 1). HRG inversely cor-
related with age (R = −0:27, p < 0:001) and fibrinogen
(R = −0:24, p = 0:003) in controls. In both CAD patients
and controls, HRG correlated negatively with platelet count
(R = −0:25, p = 0:001 and R = −0:21, p = 0:008, respectively)
and CRP (R = −0:16, p = 0:04 and R = −0:26, p = 0:001,
respectively). Interestingly, there was a positive correlation
of HRG with BT (R = 0:39, p < 0:001 and R = 0:43, p < 0:001,
respectively) in both groups. There was no difference in
HRG and VEGF between subjects whose plasma samples were
collected within the first 2 years and those from the remaining
years (data not shown).
VEGF levels were 147% higher in CAD patients compared
with controls (Table 1). VEGF correlated positively with age
(R = 0:44, p < 0:001) and fibrinogen (R = 0:26, p < 0:001)
only in controls. We observed inverse correlation between
VEGF and BT (R = −0:25, p = 0:002) in controls, but not
in CAD patients.
3.4. Fibrin Clot Properties. As expected, plasma fibrin clots
were denser (32% lower Ks) and more resistant to fibrino-
lysis (17% longer CLT) in CAD patients compared with
controls (Table 1). Comorbidities showed no associations
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with clot properties. Among medications, only ASA use
was associated with higher Ks in CAD patients
(7:0 ½6:3 − 8:0 vs:6:5 ½6:0 − 7:4 × 10−9 cm2, p = 0:01). Of
note, positive correlations between Ks and BT were observed
in both CAD (Figure 1(a)) and control (Figure 1(b)) groups.
In CAD patients (Figure 1(c)), but not in controls
(Figure 1(d)), there was also a weak inverse correlation
between CLT and BT. In both CAD patients and controls,
there were inverse correlations between Ks and FVIII
(Figures 2(a) and 2(b)), and positive correlations between
Ks and HRG (Figures 2(c) and 2(d)). VEGF inversely cor-
related with Ks (R = −0:28, p < 0:001) in controls but not
in CAD patients. HRG or VEGF showed no associations
with CLT in either group. The duration of storage at -80
degrees Celsius showed association with neither Ks nor
CLT (data not shown).
3.5. Determinants of BT. In CAD patients, univariate anal-
ysis showed that diabetes and ASA treatment were associ-
ated with higher chance of very long BT values, i.e., above
the 90th percentile (≥336 sec; Table 2). Less-dense fibrin
clot formation, defined as Ks values in the top quartile, was
a predictor of both a long (≥279 sec, the upper quartile, Sup-
plementary Table S1) and a very long BT (Table 2). HRG
levels in the upper quartile (but not CLT) were also
associated with long and very long BT (Supplementary
Table S1, Table 2). Statin use, elevated platelet count (the
upper quartile), and FVIII > 150% were in turn inversely
related to long BT (Supplementary Table S1). Multivariate
analyses showed that Ks had its predictive value for both a long
and a very long BT; high HRG levels were significantly
associated only with a very long BT and platelet count
exclusively with a long BT (Table 2 and Supplementary Table S1).
Table 1: Characteristics of study groups.
CAD patients (n = 154) Controls (n = 154) p
Age (y) 64 (59-70) 61 (58-68) 0.05
Females, n (%) 74 (48) 93 (60) 0.03
BMI (kg/m2) 28 (24-31) 24.9 (22.6-27.6) <0.001
Risk factors of CAD
Current smoking, n (%) 53 (34) 52 (34) 0.90
Arterial hypertension, n (%) 90 (58) 51 (33) <0.001
Diabetes mellitus, n (%) 24 (15.6) — —
Prior MI, n (%) 42 (27.7) — —
Treatment, n (%)
ASA 43 (28) — —
Statin 38 (25) — —
β-Blocker 39 (25) — —
ACEI 63 (41) — —
Laboratory investigations
Hemoglobin (g/dL) 14:07 ± 1:42 13:85 ± 1:31 0.16
Platelet count (× 103/μL) 241 (205-308) 238 (205-302) 0.75
Total cholesterol (mM) 5.16 (4.50-5.84) 4.88 (4.27-5.57) 0.04
LDL cholesterol (mM) 3.30 (2.75-3.95) 3.02 (2.46-3.69) 0.005
Glucose (mM) 5.3 (5.0-5.8) 5.3 (4.9-5.7) 0.31
Homocysteine (μM) 12.2 (10.1-19.1) 11.1 (10.0-15.7) 0.11
INR 1.00 (0.97-1.06) 1.00 (0.97-1.05) 0.75
APTT (sec) 27.1 (24.7-30.0) 27.2 (25.0-30.4) 0.69
FVIII (%) 142 (117-173) 131.5 (111-158) 0.009
Fibrinogen (g/L) 3.36 (2.80-4.00) 2.79 (2.37-3.22) <0.001
CRP (mg/L) 1.93 (1.40-2.58) 1.69 (1.28-2.39) 0.06
BT (sec) 235 (202-277) 424 (324-500) <0.001
CLT (min) 90 (74-106) 77 (68-88) <0.001
Ks × 10−9 cm2 6.7 (6.1-7.6) 9.8 (8.0-10.7) <0.001
VEGF (pg/mL) 72.4 (49.8-88.0) 29.3 (25.6-34.9) <0.001
HRG (μg/mL) 33.0 (28.0-40.0) 65.9 (57.2-74.2) <0.001
CAD: coronary artery disease; BMI: body mass index; MI: myocardial infarction; ASA: acetylsalicylic acid; ACEI: angiotensin-converting enzyme inhibitor;
LDL: low-density lipoprotein; INR: international normalized ratio; APTT: activated partial thromboplastin time; FVIII: coagulation factor VIII; CRP: C-
reactive protein; BT: bleeding time; CLT: clot lysis time; Ks: clot permeability; VEGF: vascular endothelial growth factor; HRG: histidine-rich glycoprotein.
Continuous variables are expressed as the mean ± standard deviation or median (interquartile range), as appropriate.
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In controls, age was associated with lower chance of both
long and very long BT (Supplementary Table S1 and
Table 2). Platelet count in the top quartile was inversely
associated with BT above the upper quartile (Supplementary
Table S1). Moreover, both Ks and HRG correlated positively
with long and very long BT, but CLT was not associated
with BT (Supplementary Table S1 and Table 2). In the
multivariate model for prediction of a very long BT
including age, current smoking, anemia, high platelet count,
FVIII above 150%, high CLT, high Ks, and high HRG, the
effects of the latter two remained significant (Table 2). In a
similar multivariate model with a long BT as the dependent
variable, the effect of age, platelet count, and HRG, but not
that of Ks, remained significant (Supplementary Table S1).
In both univariate and multivariate analyses, short BT
(i.e., below the lower quartile) was associated in CAD
patients with statin treatment as well as platelets, Ks, and
HRG below their lower quartiles (Table 3). In controls in
turn, short BT was predicted by age, low Ks, and low HRG
in univariate analysis but only the effect of Ks remained sig-
nificant in the multivariate model (Table 3).
3.6. Scar Formation. Scar formation at sites of BT measure-
ment was observed in 41 (26.6%) CAD patients and 38
(24.7%) controls. CAD patients with scars were more fre-
quently affected by diabetes and treated with ASA or statins
and had shorter BT (by 18%) compared with the remainder
(Supplementary Table S2). Control subjects with scars were
older, less frequently females and smokers compared to the
remainder. Moreover, 12% lower Ks together with 36%
higher homocysteine and 41% higher CRP (all p < 0:05)
were observed in controls who developed scars following
skin incisions (Supplementary Table S2).
Analysis of association between BT and scar formation
demonstrated that scars developed almost exclusively (in
CAD patients) or mostly (controls) in subjects with a short
(in the lower quartile) or a very long (above 90th percentile)
BT (Figure 3). Not surprisingly, univariate analyses of scar
formation predictors showed that both CAD patients with
diabetes and treated with ASA or statin, and with a short
or a very long BT, had an increased risk of scar formation
after skin incisions (Table 4). Multivariate models were
developed to assess the effect of age, diabetes, and ASA or
statin treatment on scar formation, and either a short or a
very long BT. In the first model, the effects of a short BT,
diabetes, and statin treatment remained significant. In the
other, a very long BT, statin treatment, and age were pre-
dictors of scar formation. In control subjects, both a low
and a very long BT and, additionally, age were associated
with an increased risk of scars following skin incisions in
univariate analyses. Those effects remained significant in
multivariate analyses, except for that observed for age in
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Figure 1: Correlations between bleeding time and fibrin clot permeability (Ks (a, b)) and lysis time (c, d) in CAD patients (n = 154; a, c) and
controls (n = 154; b, d). p values calculated using Spearman’s rank correlation coefficient.
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the model involving a short BT (Table 4). A long BT (the
top quartile) was associated with impaired wound healing
only in the control group (Supplementary Table S3).
4. Discussion
To our knowledge, this study is the first to show that
increased permeability of plasma fibrin clots is correlated
with longer BT in human subjects. We demonstrated that
Ks is an independent predictor of longer BT in both studied
groups suggesting that fibrin network density affects bleeding
time and has the impact on the primary hemostasis. Another
novel finding is that elevated HRG in circulating blood corre-
lates with longer BT in humans, which suggests that this
abundant protein may affect primary hemostasis at least in
part through its impact on fibrin clot structure. We showed
an interesting U-shaped relationship between BT and scar
formation following skin incisions, suggesting that appropri-
ate skin wound healing is associated with medium BT. The
current study expands our knowledge on the role of fibrin
clot properties in primary hemostasis and wound healing in
healthy subjects and cardiovascular patients, independently
of fibrinogen and platelet count.
Previously, it has been shown that plasma fibrin clot
characteristics may influence bleeding risk as observed in
women with heavy menstrual bleeding [29] and patients with
atrial fibrillation receiving vitamin K antagonists [30]. To our
knowledge, there have been no published reports suggesting
that mucocutaneous bleeding or bleeding from superficial
skin injuries in healthy subjects may be linked to fibrin clot
properties determined in plasma-based assays. The present
study shows that apart from platelet count, the density of
plasma fibrin clots could contribute to BT independently of
fibrinogen concentrations, suggesting a significant involve-
ment of fibrin in primary hemostasis in health and pro-
thrombotic states with their commonest representative,
CAD. Recently, Macrae et al. [31] have described a thin fibrin
biofilm covering a blood clot at the contact with air. Whether
this phenomenon might contribute to shorter BT in subjects
with denser clot network formation which could facilitate
formation of fibrin biofilm following skin injury is worth
investigating. Interesting relationships between the mass of
the clot fibrin matrix and the balance of pro- and antiangio-
genic factors were shown by Hadjipanayi et al. [32]. Increas-
ing the clot mass shifted the balance towards proangiogenic
VEGF instead of antiangiogenic PF4. Also, clot hypoxia pro-
moted proangiogenic factors. Moreover, EC migration into
the fibrin matrix was enhanced proportionally to increasing
mass of the clot matrix. These observations suggest that the
matrix controls the process of transition from hemostasis to
angiogenesis by regulation of pro- and antiangiogenic bal-
ance. However, these observations provide little insight into
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Figure 2: Correlations between fibrin clot permeability (Ks) and FVIII (a, b) and HRG (c, d) in CAD patients (n = 154; a, c) and controls
(n = 154; b, d). p values calculated using Spearman’s rank correlation coefficient.
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the relationship between the characteristics of the fibrin clot
arising from its spatial structure and the ability to heal the
wound properly.
In our study, BT was shorter in CAD patients com-
pared to controls, which corroborates with earlier findings
[33], but also in subjects who formed dense fibrin clots
based on the plasma-based assays. Fibrin is formed within
tens of seconds from vascular injury [25], but the stability
and function of the resultant fibrin clot depends on its
spatial structure impacting the properties of the thrombus
at the site of injury. The relationship between clot suscep-
tibility to lysis and BT was weak and detectable only in
CAD patients, suggesting a negligible impact of clot lysa-
bility measured in vitro on BT.
Table 2: Determinants of a very long bleeding time (BT, above the 90th percentile) in coronary artery disease (CAD) patients and controls.
Variable
CAD patients (BT ≥ 336 sec) Controls (BT ≥ 568 sec)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age (y) 1.01 (0.94-1.09) 0.75 1.01 (0.89-1.13) 0.95 0.77 (0.66-0.90) <0.001 0.83 (0.69-1.01) 0.06
Current smoking 0.61 (0.19-1.98) 0.41 1.07 (0.20-5.79) 0.94 1.08 (0.38-3.10) 0.89 1.56 (0.37-6.49) 0.54
Diabetes 4.00 (1.30-12.34) 0.016 1.70 (0.24-12.00) 0.59 — —
Anemia 2.09 (0.61-7.15) 0.24 1.70 (0.16-17.78) 0.66 0.51 (0.06-4.11) 0.53 1.49 (0.13-16.36) 0.76
ASA treatment 2.94 (1.03-8.43) 0.044 1.84 (0.37-9.04) 0.45 — —
Statin treatment 0.18 (0.02-1.43) 0.10 0.18 (0.01-2.24) 0.18 — —
Platelet count in the
top quartile (≥308 and
≥302 × 103/μL)∗
0.65 (0.18-2.43) 0.53 1.59 (0.20-12.47) 0.66 0.16 (0.02-1.27) 0.08 0.18 (0.02-1.81) 0.15
FVIII > 150% 0.78 (0.27-2.27) 0.65 2.51 (0.47-13.22) 0.28 0.50 (0.14-1.84) 0.30 1.62 (0.31-8.50) 0.57
CLT in the top quartile
(>106 and >88min)∗ 0.39 (0.08-1.80) 0.23 0.71 (0.10-5.11) 0.73 0.97 (0.30-3.18) 0.96 0.73 (0.141-3.85) 0.72
Ks in the top quartile (>7.6
and ≥10:7 × 10−9 cm2)∗ 20.58 (5.44-77.85) <0.001 23.70 (4.65-120.8) <0.001 19.92 (5.33-74.44) <0.001 10.89 (2.31-51.44) 0.003
HRG in the top quartile
(≥40 and ≥74.2 μg/mL)∗ 11.79 (3.53-39.33) <0.001 10.27 (2.05-51.31) 0.005 4.01 (1.42-11.29) 0.009 4.54 (1.07-19.27) 0.040
OR: odds ratio; CI: confidence interval; otherwise, see Table 1. ∗Cutoffs for CAD patients and controls, respectively, are given.
Table 3: Determinants of a short bleeding time (BT, the lower quartile) in coronary artery disease (CAD) patients and controls.
Variable
CAD patients (BT< 202 sec) Controls (BT< 324 sec)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age (y) 1.02 (0.97-1.08) 0.41 1.01 (0.95-1.08) 0.69 1.20 (1.12-1.28) <0.001 1.10 (1.00-1.21) 0.06
Current smoking 1.34 (0.63-2.86) 0.45 1.50 (0.57-3.99) 0.42 0.53 (0.23-1.22) 0.13 0.54 (0.18-1.62) 0.27
Diabetes 0.77 (0.27-2.24) 0.64 1.24 (0.31-4.87) 0.76 — —
Anemia 1.41 (0.53-3.74) 0.49 1.11 (0.30-4.07) 0.87 1.45 (0.47-4.46) 0.52 1.61 (0.37-7.10) 0.53
ASA treatment 0.62 (0.26-1.48) 0.28 0.42 (0.12-1.44) 0.17 — —
Statin treatment 2.24 (1.01-4.97) 0.048 4.34 (1.44-12.97) 0.01 — —
Platelet count in the
lower quartile (≤205
and ≤205× 103/μL)∗
0.18 (0.05-0.63) 0.007 0.22 (0.05-0.92) 0.038 0.37 (0.13-1.02) 0.05 0.36 (0.10-1.32) 0.12
FVIII > 150% 1.11 (0.53-2.32) 0.79 0.65 (0.23-1.83) 0.41 1.96 (0.90-4.24) 0.09 0.66 (0.21-2.05) 0.48
CLT in the lower quartile
(≤74 and <68min)∗ 0.73 (0.30-1.77) 0.49 1.02 (0.33-3.16) 0.97 0.93 (0.39-2.20) 0.87 2.53 (0.77-8.33) 0.13
Ks in the lower quartile
(<6.1 and ≤8 × 10−9 cm2)∗ 4.32 (1.94-9.60) <0.001 3.35 (1.15-9.73) 0.027 21.27 (8.47-53.44) <0.001 10.02 (2.45-40.97) 0.001
HRG in the lower
quartile (≤28 and
≤56.9μg/mL)∗
9.23 (4.04-21.07) <0.001 9.19 (3.50-24.29) <0.001 3.11 (1.40-6.87) 0.005 1.11 (0.36-3.41) 0.85
For a list of abbreviations, see Tables 1 and 2. ∗Cutoffs for CAD patients and controls, respectively, are given.
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The current study is the first to show that plasma levels of
HRG are involved in primary hemostasis in both CAD
patients and controls. We found that HRG correlated posi-
tively with BT, which provides evidence for a role of this anti-
coagulant and antifibrinolytic protein in vivo in humans.
HRG interacts with fibrinogen while assessed in vitro which
leads to the formation of less compact fibrin clots [18]. In
animal models, HRG deficiency has been reported to
enhance thrombin generation and promote arterial throm-
bosis [34]. It is estimated that nearly 50% of plasminogen cir-
culates bound to HRG, which reduces plasminogen available
to bind fibrin [19, 35]. Moreover, HRG can be incorporated
into fibrin clots and its presence causes the formation of thin-
ner fibrils as demonstrated in a purified system. Vu et al. [36]
demonstrated that HRG competes with thrombin for binding
site of γ′-fibrinogen, known to increase fibrin clot density
Table 4: Determinants of scar formation following bleeding time (BT) measurement in coronary artery disease (CAD) patients and controls
(including a short and a very long BT).
Variable CAD patients p Controls p
Univariate analysis
Age (y) 1.04 (0.99-1.10) 0.10 1.06 (1.01-1.12) 0.021
Diabetes 3.48 (1.42-8.57) 0.007 —
ASA treatment 2.37 (1.11-5.07) 0.026 —
Statin treatment 2.26 (1.03-4.94) 0.042 —
BT above the 90th percentile (≥336 and ≥568 sec)∗ 7.92 (2.55-24.56) <0.001 5.56 (1.94-15.91) 0.001
BT in the lower quartile (<202 and <324 sec)∗ 12.02 (5.12-28.21) <0.001 6.05 (2.69-13.62) <0.001
Multivariate model with BT above the 90th percentile
Age (y) 1.06 (1.00-1.13) 0.035 1.12 (1.05-1.19) <0.001
Diabetes 2.65 (0.91-7.68) 0.07 —
ASA treatment 1.19 (0.47-3.00) 0.72 —
Statin treatment 3.91 (1.51-10.13) 0.005 —
BT above the 90th percentile (≥336 and ≥568 sec)∗ 10.17 (2.88-35.97) <0.001 14.76 (4.29-50.77) <0.001
Multivariate model with BT below the lower quartile
Age (y) 1.05 (0.99-1.12) 0.12 1.00 (0.94-1.07) 0.94
Diabetes 5.10 (1.59-16.30) 0.006 —
ASA treatment 3.56 (1.19-10.66) 0.024 —
Statin treatment 1.53 (0.53-4.37) 0.43 —
BT below the lower quartile (<202 and <324 sec)∗ 21.87 (7.41-64.55) <0.001 5.94 (2.29-15.41) <0.001
For a list of abbreviations and legends, see Tables 1 and 2.
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Figure 3: Distribution of bleeding time (BT) values in CAD patients (n = 154; a) and controls (n = 154; b) with and without scars following
BT measurement.
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[37]. On the other hand, Kotzé et al. [38] have shown that
fibrin clot properties are related to cardiovascular risk factors
independently of γ′-fibrinogen levels. The present study
demonstrated that higher HRG levels are associated with
looser plasma clot networks in human subjects, suggesting
additional anticoagulant effects of HRG reported in vitro
[18, 19, 34, 35]. The study performed in HRG-deficient mice
showed higher spontaneous fibrinolytic activity but shorter
prothrombin and bleeding time in the absence of HRG com-
pared to controls [39]. The present study failed to show any
associations between HRG and CLT; however, we cannot
exclude that other assays used to assess fibrinolysis might
show antifibrinolytic effects of this protein suggested by
in vitro experiments. Of note, the presence of HRG in plasma
clots in patients with deep vein thrombosis has been shown
recently [40]. Taken together, the current findings suggest
that HRG is involved in human hemostasis and may modu-
late fibrin clot structure in vivo.
Unexpectedly, a very long as well as a short BT corre-
lated with skin scar formation. We hypothesized that more
compact and less permeable clots would be associated with
impaired wound healing due to attenuated fibroblast inva-
sion into the wound space filled with dense fibrin network
[12]. As longer BT was associated with less compact and
more permeable fibrin network, it may be presumed that
longer bleeding impairs formation of the provisional scaf-
fold necessary for successful wound healing [12, 41]. We
failed to observe association between fibrin clot properties
and scar formation. It might suggest that the structure of
fibrin clots in a range encountered in most human subjects
(without extremes) is sufficiently “loose” to ensure appro-
priate wound healing, with no major impact on formation
of skin scars or not. A strong negative correlation between
scar formation and platelet count in the control group sup-
ports the role of platelets not only in the primary hemosta-
sis but also in proper clot contraction and secretion of
growth factors indispensable for appropriate healing. We
did not show the same correlation in the CAD group, likely
due to more frequent ASA use. Therefore, an intriguing
finding that scar formation is associated with a short or a
very long BT is hard to explain. It may be hypothesized
that scar formation is associated with various processes
depending on whether a subject has either a short or a very
long BT. It is also possible that proper wound healing
requires the good quality of the skin and its vessels along
with optimal blood coagulation, reflected at least in part
by an “average” BT and all alterations lead to defective tis-
sue repair facilitating scar formation. We also noted that
CAD patients with scars were more frequently diabetic
and treated with ASA or statins than those without scars.
Diabetes is known to increase density of fibrin clots, while
both aspirin and statins have been reported to render clot
networks looser, though not in diabetic patients [9, 42].
Our observations indicate that skin scar formation is influ-
enced by comorbidities and medications used with a partic-
ular impact of diabetes. Since the ability of proper wound
healing depends on multiple environmental or acquired
variables [43], we identified new potential modulators of
this complex process. Further research is needed to eluci-
date regulation of skin scar formation and its potential
practical implications, e.g., for treatment of bleeding, surgi-
cal and trauma wounds, chronic skin ulcers, bedsores, and
in plastic surgery.
Interestingly, we observed inverse correlations between
VEGF and BT as well as between VEGF and Ks in con-
trols, but not in CAD patients. Most likely, these associa-
tions reflect the impact of endothelial damage, along
with platelets as an important source of circulating VEGF,
a major growth factor stimulating angiogenesis during
wound healing [44, 45]. Despite higher circulating VEGF
levels in the CAD group, we did not observe any correla-
tion between VEGF and scar formation, which might have
been expected as a result of impaired neovascularization
[43]. This issue requires further studies.
The current study has several limitations. The number of
subjects in the study was limited; however, the study was ade-
quately powered to detect significant differences in fibrin clot
characteristics. It should be noted that the observed associa-
tions do not necessarily mean the cause-effect relationship.
Several other factors that may modulate clot properties have
not been assessed, for example, complement C3, fibronectin,
and some genetic determinants [6, 7]. We also did not mea-
sure levels of γ′-fibrinogen, which is known to alter clot
structure [11, 46], which could be one of additional contrib-
utors to the phenomena described here; however, given prev-
alence of this variant, it is unlikely that γ′-fibrinogen explains
all differences and associations observed by us. The same
holds true for factor XIII levels, a potent modulator of fibrin
clot structure [47]. Moreover, we did not measure von Will-
ebrand factor, which may influence clot structure and BT.
Furthermore, to better characterize fibrin clot properties,
scanning electron microscopy of clots and thromboelastogra-
phy could be used in future studies. The use of other tech-
niques including the PFA-100 and ROTEM would be
helpful in assessment of the association between fibrin clot
properties and bleeding; however, such analyses were beyond
the scope of this hypothesis-generating study and will be
applied in future studies. Finally, in vitro experiments, espe-
cially elucidating the impact of HRG and VEGF on clots,
are needed to get more mechanistic insights into the phe-
nomena presented; however, this study is hypothesis-
generating and strongly supports further research in this field
given observations made in patients and control subjects.
To conclude, this study indicates that fibrin clot structure
may affect BT in humans, suggesting a role of fibrin proper-
ties in primary hemostasis. The current study demonstrated a
potential role of circulating HRG in primary hemostasis and
its possible impact on fibrin clot structural properties. Fur-
ther studies are warranted to elucidate complex relationships
between plasma fibrin clot phenotype and wound healing,
which might have important practical implications.
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